<DOC>
	<DOCNO>NCT00746447</DOCNO>
	<brief_summary>This study intend study efficacy tolerability daily 3.0 g mesalazine granule vs. daily 1.5 g mesalazine granule vs. three time daily 0.5 g mesalazine granule maintenance remission patient ulcerative colitis</brief_summary>
	<brief_title>Once Daily ( OD ) Versus Three Times Daily ( TID ) Dosing With Mesalazine Granules Prevention Recurrence Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Signed informed consent , Men woman age 18 75 year , Historically confirm diagnosis ulcerative colitis endoscopy histology , Patient remission , define ( accord Rachmilewitz ) : Clinical Activity Index ( CAI ) &lt; = 4 , Endoscopic Index ( EI ) &lt; 4 , Extent inflammation last acute episode &gt; 15 cm beyond anal margin , Last acute episode end within 3 month prior study entry . Crohn 's disease , Prior bowel resection lead diarrhoea , Toxic megacolon , Gastric duodenal ulcer , Haemorrhagic diathesis , Presence symptomatic organic disease gastrointestinal tract ( exception haemorrhoid hiatal hernia ) , Active colorectal cancer history colorectal cancer , Serious secondary illness acute chronic nature , Asthma , Severe impairment renal ( e.g. , serum creatinine &gt; 1.5 mg/dl ) and/or liver function ( e.g. , serum transaminase [ ALT and/or AST ] alkaline phosphatase &gt; =2x upper limit normal [ ULN ] ) , Application immunosuppressant within 3 month and/or corticosteroid ( oral , intravenous [ IV ] topical rectal ) within 30 day prior baseline , Application nonsteroidal antiinflammatory drug ( NSAIDs ) long term treatment ( i.e . &gt; 6 week ) , acetylsalicylic acid ( &lt; = 350 mg/day ) , paracetamol , Known intolerance/hypersensitivity salicylic acid derivative constituent study drug , Wellfounded doubt patient 's cooperation , Existing intend pregnancy , breastfeeding , Women childbearing potential without adequate contraceptive protection , e.g. , hormonal contraception , intrauterine device ( IUD ) , doublebarrier method contraception ( e.g. , use condom spermicide ) , partner undergone vasectomy subject monogamous relationship . The investigator responsible determine whether subject adequate birth control study participation , Participation another clinical trial within last 30 day , simultaneous participation another clinical trial , previous participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>maintenance</keyword>
	<keyword>5-ASA</keyword>
	<keyword>mesalamine</keyword>
	<keyword>mesalazine</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>